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Abstract
Eighty-one patients affected by the novel inﬂuenza A (H1N1),
hospitalized in North-western Italy, were studied. The median
age was 32 years (range 1–81 years). Fifty-six (69%) had an
underlying medical condition, including lung disorders (asthma or
chronic obstructive pulmonary disease) in 34% and obesity in 25%.
Fifty percent of them had pneumonia, 12% were admitted to the
intensive care unit and 3% died. Antiviral treatment was initiated in
75% of patients started within 48 h. Older age and lung and neuro-
cognitive disorders were associated with severe disease and death.
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Introduction
Subsequent to the identiﬁcation of the novel inﬂuenza virus
A (H1N1) in the USA and Mexico, cases of inﬂuenza-like
illness and pneumonia due to this virus have been detected
in an increasing number of countries [1,2]. To date, human
infection with the novel A (H1N1) virus has been identiﬁed
in 191 countries and territories [2]. The inﬂuenza A (H1N1)
virus contains a unique combination of gene segments that
has not previously been identiﬁed in humans or animals
[3,4]; thus, information on the clinical spectrum of illness,
risk factors for severity among persons hospitalized for the
treatment of A (H1N1) inﬂuenza and clinical management is
helpful [5–9]. The great majority of individuals infected with
the A (H1N1) virus experience uncomplicated inﬂuenza-like
illness, with full recovery within 1 week, even without medi-
cal treatment, whereas a small subset of patients develop
severe progressive disease. Primary viral pneumonia is the
most common ﬁnding in severe cases [5], but secondary bac-
terial infections play a role in approximately 30% of fatal
cases [6]. Hospitalized patients are often affected by other
medical conditions, such as diabetes and cardiovascular, neu-
rological and pulmonary diseases [5,7,8]. In the present
study, we report the main clinical ﬁndings and risk factors
for severe diseases in patients hospitalized in the Liguria
Region, in North-western Italy.
Patients and Methods
Patients presenting with inﬂuenza-like illness (temperature
‡38C and cough or sore throat) or other symptoms consis-
tent with inﬂuenza, and who were hospitalized for at least
24 h between 1 July and 30 November 2009, were included
in the study. In all these patients, infection with the novel
inﬂuenza virus A (H1N1) was conﬁrmed by real-time
RT-PCR. The CDC RT-PCR protocol and block PCR
(Seeplex FluA ACE subtyping; Seegene, Rockville, MD, USA)
were used for detection and characterization of pandemic
2009 H1N1 inﬂuenza virus [10].
Clinical records of the study participants were reviewed
in the ﬁve infectious diseases clinics participating in the
study. A standardized form, including demographic data,
underlying medical conditions, clinical signs and symptoms,
selected laboratory tests, radiographic ﬁndings, treatment
course, and outcome, was used for data collection. The
body mass index (BMI; kg/m2) was calculated for patients
for whom height and weight were available, aiming to deter-
mine whether the patient was obese (obesity was deﬁned
as a BMI >30 in adults 18 years of age or older or a BMI
percentile of 95–100 in children aged 2–18 years); the BMI
was not calculated for pregnant women. We performed a
univariate analysis to compare the characteristics of patients
who were admitted to the intensive care unit (ICU) or
died with those who were admitted to other wards and
survived.
Results
Overall, 81 patients were studied. The clinical characteristics
are outlined in Table 1. The median age was 32 years (range
1–81 years); most patients were Caucasian (85%) and 36
were female (only two women were pregnant). Symptoms at
presentation included fever (100%) and cough (82%). Diar-
rhoea or vomiting was reported in 18% of the patients. The
median time from the onset of illness to hospital admission
was 2 days (range 0–9 days). Of the 81 patients, 56 (69%)
had an underlying medical condition, including lung disorders
(asthma or chronic obstructive pulmonary disease) in 34%
and obesity in 25%. On admission, 25 patients (31%) had
leucopaenia, 13 (16%) had leucocytosis and 22 (27%) had
thrombocytopaenia. All the patients underwent a chest
X-ray on admission and 51 (63%) had ﬁndings consistent
with pneumonia. Radiographic ﬁndings included interstitial
inﬁltrates in 31 patients and parenchymal lesions in 20 (an
inﬁltrate limited to one lobe in 16 and multilobar inﬁltrates
in four individuals).
Regarding the use of antiviral drugs, 69 (85%) received
oseltamivir. Antiviral therapy was initiated within 1–9 days
(median time of 2 days) after the onset of symptoms; 75%
patients (52/69) started within 48 h. Overall, 62 patients
(76%) also received antibacterial therapy. The median length
of hospitalization was 5 days (range 1–21 days).
Ten patients (12%) were admitted to an ICU. The differ-
ence between patients who were admitted to the ICU and
those who were not is shown in Table 2. Patients admitted to
the ICU were older than the others. All ICU patients had
underlying medical conditions (mostly lung disease, neuro-
cognitive disorders and obesity) vs. only 65% of the other
participants (v2, p 0.02). Patients admitted to the ICU were
more likely to be of older age, as well as have lung and neuro-
cognitive disorders (Alzheimer’s disease, vascular neurocogni-
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tive disorder, schizophrenia, frontotemporal degeneration)
and X-ray conﬁrmed pneumonia.
Overall, two (3%) died; both of them had been admitted
to the ICU for mechanical ventilation. Death occurred after
13 days in an heart transplant recipient who developed a
mixed interstitial and alveolar radiographic lesions, and after
10 days in a resident of a long-term psychiatric facility who
developed multi-organ failure and secondary bacterial pneu-
monia.
Discussion
Most information available on clinical presentation and out-
come, and risk factors for severe disease associated with
infection with the novel inﬂuenza virus, comes from the
Americas and Oceania, whereas very limited information is
available from European countries, especially from Italy and
other Mediterranean countries. The comparison with North-
ern and Central American case series shows some differ-
ence. First, the median age of our patients was higher [7,8].
Furthermore, the rate of pneumonia was unexpectedly
higher compared to previous studies [8]. With regard to risk
factors for severe disease, we found age and lung and neuro-
cognitive disorders to be associated with the need of inten-
sive care. This is consistent with data from Mexico and the
USA, showing that the risk of death increases with age [11]
and that neurodevelopmental disorders are associated with a
negative outcome in infected children [12]. Other underlying
conditions, such as cardiological disorders and a high BMI,
tended to be associated with severe disease, as deﬁned by
admission to the ICU, although the difference was not statis-
tically signiﬁcant, probably as a result of the limited number
of patients. The present study has several limitations. We
evaluated only patients with conﬁrmed 2009 H1N1 infection,
so the group may not be representative of hospitalized
patients who may not have been tested. The hospitalization
criteria in the participating centres were different and there-
fore were subject to reporting bias. With regard to age, it is
possible that paediatric cases were under-represented as a
result of pediatric departments not participating in the study.
In conclusion, with the exception of higher age and rate
of pneumonia, our ﬁndings are consistent with those from
the Americas. In particular, older age as well as lung and
neurocognitive disorders were associated with severe dis-
eases leading to admission to the ICU. The identiﬁcation of
these factors is key to guiding the prevention and manage-
ment of the novel inﬂuenza A (H1N1).
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TABLE 1. Characteristics of hospitalized patients who were
infected with the 2009 novel inﬂuenza A (H1N1) virus in
Italy
Characteristic N = 81 (100%)
Male sex 45 (55)
Age, median (range), years 32 (1–81)
Age group (years)
0–10 5 (6)
11–17 11 (14)
18–49 50 (62)
50–64 9 (11)
‡65 6 (7)
Race or ethnic group
Caucasian 69 (85)
Hispanic (South America) 12 (15)
Underline medical conditions
At least one 56 (69)
Lung disorders (asthma or COPD) 19/56 (34)
BMI >30 14/56 (25)
Immunosuppressiona 12/56 (21)
Cardiovascular disease 12/56 (21)
Neurocognitive disorders 9/56 (16)
Chronic renal failure 6/56 (11)
Diabetes 5/56 (9)
Selected laboratory abnormalities
Leucopaenia (<5000 per mm3) 25 (31)
Leucocytosis (>11 000 per mm3) 13 (16)
Trombocytopaenia (<150 000) 22 (27)
AST/ALT elevation (>2 fold normal) 4 (5)
Pneumonia
Any type 51 (63)
Interstitial infultrates 31/51 (61)
Lobar inﬁltrates 20/51 (39)
aNeutropenia, 3; heart transplant, 2; haematological malignancy and haemato-
poietic stem cell transplant, 2; HIV, 2; other, 3.
ALT, alanine aminotranferease; AST, aspartate aminotransferase; BMI, body mass
index; COPD, chronic obstructive pulmonary disease.
TABLE 2. Univariate analysis of hospitalized patients who
were not admitted to intensive care unit (ICU) and survived
and patients who were admitted to an ICU or died
Characteristic
Not ICU,
N = 71, n (%)
ICU or
deceased,
N = 10, n (%) p
Age, median (range), years 29.5 (1–81) 43.5 (20–79) 0.04
At least one underline medical
conditions
46/71 (65%) 10/10 (100%) 0.02
Neurocognitive disorders 5 (7%) 3 (33.3%) 0.02
BMI >30 11 (15.5%) 3 (33.3%) 0.25
Lung disorders (asthma or COPD) 14 (19.7%) 5 (50%) 0.03
Cardiovascular disease 9 (12.3%) 3 (33.3%) 0.14
Chronic renal failure 6 (8.5%) 0 0.33
Diabetes 5 (7.0%) 0 038
Immunosuppression 11 (15%) 1 (10%) 0.64
Antibacterial treatment 49 (69%) 10 (100%) 0.11
Pneumonia on admission 31 (44%) 10 (100%) 0.0008
Days from onset of symptoms to
treatment, median (range)
2 (0–9) 1.5 (0–6) 0.35
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